Results 61 to 70 of about 195,293 (269)

Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels [PDF]

, 2015
BACKGROUND: The German Lipoprotein Apheresis Registry (DLAR) has been initiated by members of the Nephrology Foundation (WiNe), the German association of kidney centres (DN), the German society of nephrology (DGfN) and additional medical associations ...
Christian Peter, Class L. Neumann, Eberhard Roeseler, Franz Heigl, null null, Thomas Zimmermann, Ulrich Julius, Volker J. J. Schettler   +7 more
core   +1 more source

Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a)

Antioxidants, 2021
Aims: An abundance of epidemiological evidence demonstrates that elevated lipoprotein(a) (Lp(a)) represents a significant contributing risk factor towards the development of cardiovascular disease.
Tina Z. Khan, Adam Hartley, Dorian Haskard, Mikhail Caga-Anan, Dudley J. Pennell, Peter Collins, Mahmoud Barbir, Ramzi Khamis   +7 more
doaj   +1 more source

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9 [PDF]

, 2017
BACKGROUND: A beneficial effect on cardiovascular risk may be obtained by improving lipid-related serum lipoprotein functions such as high-density lipoproteins (HDLs) cholesterol efflux capacity (CEC) and serum cholesterol loading capacity (CLC) and by ...
Adorni, Maria Pia, Bernini, Franco, Ferri, Nicola, Izzo, Raffaele, Marchiano, Silvia, Rozza, Francesco, Trimarco, Valentina, Zimetti, Francesca   +7 more
core   +3 more sources

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1835-1847, November 2025.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

LDL apheresis or PCSK9 inhibition? Sometimes we have to combine them

, 2017
This study presents the case of a female patient with severe heterozygous familial hypercholesterolemia. Despite the combined maximum dose oral treatment with rosuvastatin and ezetimibe, we found markedly elevated lipid parameters.
M. Harangi, L. Juhász, B. Nádró, J. Balla, G. Paragh   +4 more
semanticscholar   +1 more source

Homozygous familial hypercholesterolemia with stenosis of the left anterior descending coronary artery successfully treated with weekly low‐density lipoprotein apheresis for 16 years without percutaneous coronary intervention

Clinical Case Reports, 2019
We successfully treated a patient with homozygous familial hypercholesterolemia (HoFH) with stable coronary arterial disease using optimal medical therapy and low‐density lipoprotein (LDL) apheresis for 16 years without percutaneous coronary intervention
Takanori Yasu, Masahiro Shimoyama, Hiroshi Wada, Tomohiro Iwakura, Shigeru Toyoda, Atsuhiko Kawabe, Takushi Sugiyama   +6 more
doaj   +1 more source

Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) [PDF]

, 2017
Primary dyslipidemias are a heterogeneous group of disorders characterized by abnormal levels of circulating lipoproteins. Among them, familial hypercholesterolemia is the most common lipid disorder that predisposes for premature cardiovascular disease ...
Angelico, F., Arca, M, Averna, M., Bertolini, S, Calandra, S, Casula, M, Catapano, Al, Cefalù, Ab, Del Ben, M., Lipigen, Group, Maranghi, M, Montali, A., Noto, D, Tarugi, P.   +13 more
core   +1 more source

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, Volume 27, Issue S8, Page 34-46, September 2025.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Successful Treatment Of Homozygous Familial Hypercholesterolemia Using Cascade Filtration Plasmapheresis

Turkish Journal of Hematology, 2012
OBJECTIVE: The aim of our study is to discuss the efficacy of low-density lipoprotein-cholesterol (LDL-C) apheresis procedure using the cascade filtration system for pediatric patients with homozygous familial hypercholesterolemia (FH), and to clarify ...
Fatih Kardas, Aysun Cetin, Musa Solmaz, Ruksan Buyukoglan, Leylagul Kaynar, Mustafa Kendirci, Bulent Eser, Ali Unal   +7 more
doaj   +1 more source

Spectrum of cardiovascular manifestations in homozygous familial hypercholesterolemia

Journal of Marine Medical Society, 2023
Homozygous familial hypercholesterolemia (HoFH) is a rare, primarily an autosomal dominant genetic disorder that causes markedly elevated low-density lipoprotein (LDL) cholesterol levels predisposing patients to risk of developing premature ...
Nitin Bajaj, Balbir Singh, Ananthkrishnan Ramamoorthy, Arijit Kumar Ghosh   +3 more
doaj   +1 more source